Affordable Access

deepdyve-link deepdyve-link
Publisher Website

PIKing the right patient.

Authors
  • Turke, Alexa B
  • Engelman, Jeffrey A
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
Jul 15, 2010
Volume
16
Issue
14
Pages
3523–3525
Identifiers
DOI: 10.1158/1078-0432.CCR-10-1201
PMID: 20538763
Source
Medline
License
Unknown

Abstract

HER2 amplification and PIK3CA mutation were validated as biomarkers for sensitivity to the single-agent phosphoinositide 3-kinase (PI3K) inhibitor, GDC-0941, in breast cancer models. A novel expression profile was developed to identify other breast cancers sensitive to PI3K inhibitors. These expression studies highlighted feedback networks connecting TORC1, PI3K, and mitogen-activated protein kinase (MAPK) pathways, and underscored the potential for combination therapies.

Report this publication

Statistics

Seen <100 times